Pemphigus and Bullous Pemphigoid Treatment Denied: How to Appeal

Pemphigus and bullous pemphigoid are rare, life-threatening autoimmune blistering diseases. Without proper treatment, they can be fatal. Yet patients with these conditions routinely face insurance denials for rituximab (Rituxan), IVIG, and even high-dose corticosteroids. If you've been denied, the rarity of your condition is not a reason to give up — it's a reason to appeal with strong clinical documentation.

Understanding the Two Conditions

Pemphigus vulgaris and pemphigus foliaceus: Autoimmune blistering affecting the mucous membranes (mouth, throat, genitals) and skin. Painful erosions can prevent eating and speaking. IgG antibodies target desmoglein proteins. Untreated pemphigus has historically had significant mortality.

Bullous pemphigoid (BP): More common than pemphigus, typically in elderly patients. Large, tense blisters on skin without mucosal involvement. IgG antibodies target BP180 and BP230 proteins. Can resolve spontaneously but requires treatment to prevent complications in frail elderly patients.

Why Rituximab for Pemphigus Is Denied

Rituximab (Rituxan, a CD20-targeted monoclonal antibody) was FDA-approved for pemphigus vulgaris in 2018, making it the first approved biologic for this indication. Despite this, denials occur because:

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization requirements for steroid failure: Insurers may require failure on high-dose prednisone and adjuvants (azathioprine, mycophenolate, dapsone) before rituximab.

Off-label use for pemphigus foliaceus: Rituximab's FDA approval is specific to pemphigus vulgaris. Pemphigus foliaceus treatment may be denied as off-label, requiring peer-reviewed literature support.

Dosing disputes: Rituximab for pemphigus uses a specific dosing regimen (1000mg IV x2 doses 2 weeks apart, then 500mg at 12 and 18 months). Insurer reviewers may not be familiar with this protocol.

Step therapy requirements: Some payers require exhausting multiple immunosuppressants before rituximab, despite clinical guidelines supporting early rituximab use to reduce cumulative corticosteroid burden.

Your appeal should cite the FDA approval (for pemphigus vulgaris), the RITUX 3 trial data (rituximab superior to prednisone alone), and AAD/IPPF guidelines.

IVIG for Bullous Pemphigoid and Refractory Cases

IVIG (intravenous immunoglobulin) is used for severe or refractory bullous pemphigoid, refractory pemphigus, and as a steroid-sparing agent. Insurance denials for IVIG in blistering disorders are common.

Appeal arguments:

• Document disease severity using BSAS (Bullous Skin Assessment Score) — quantifies affected BSA and blistering activity
• Document steroid failure or contraindications to corticosteroid doses required for control (osteoporosis, diabetes, glaucoma, psychiatric history)
• Reference IVIG as evidence-based therapy in published AAD and dermatology society guidelines
• Document serum autoantibody levels (anti-Dsg1, anti-Dsg3 for pemphigus; anti-BP180, anti-BP230 for BP) as objective disease markers

Documenting Prednisone Use and Dose

Most blistering disorder protocols begin with prednisone. Insurance appeals for advanced therapy must document:

• Starting dose (pemphigus typically requires 1–1.5 mg/kg/day prednisone for initial control)
• Duration of high-dose steroid use
• Complications of corticosteroid therapy: weight gain, hyperglycemia, osteoporosis, mood changes, avascular necrosis
• Failed adjuvant immunosuppressants: azathioprine, mycophenolate mofetil, dapsone, cyclophosphamide

This documentation establishes both treatment-refractory disease and the medical necessity of steroid-sparing agents.

Severity Scoring Tools

BSAS (Bullous Skin Assessment Score): Measures BSA involvement and activity in bullous pemphigoid. Higher scores indicate more severe disease.

Pemphigoid score / PDAI (Pemphigus Disease Area Index): Quantifies skin and mucosal involvement for pemphigus. Scores are useful in establishing disease burden for insurance reviewers.

Document these scores at each visit and include them in prior authorization letters.

IPPF and Orphan Disease Resources

The International Pemphigus and Pemphigoid Foundation (IPPF, pemphigus.org) provides patient advocacy resources, including model appeal letters and clinical expert referrals. IPPF-connected academic dermatology centers can provide second opinions that strengthen appeals and External Independent Review: Complete Guide" class="auto-link">external review requests.

For external appeals, an IROs) Explained" class="auto-link">independent review organization (IRO) that includes a dermatologist with expertise in autoimmune blistering diseases has a much higher probability of reversing a denial than a general internist reviewer.

Fight Back With ClaimBack

ClaimBack's rare disease appeal tools are designed for patients with pemphigus and bullous pemphigoid, with BSAS documentation templates, rituximab FDA approval evidence, and IPPF resource integration.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal